innovance pfa 200 system (Siemens Healthineers)
86
Structured Review
Siemens Healthineers
innovance pfa 200 system
Innovance Pfa 200 System, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfa/analyzer+function+platelet/pmc13202023-72-19-22
Average 86 stars, based on 1 article reviews
Innovance Pfa 200 System, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfa/analyzer+function+platelet/pmc13202023-72-19-22
Average 86 stars, based on 1 article reviews
innovance pfa 200 system - by Bioz Stars,
2026-09
86/100 stars
Images
1) Product Images from "PSG6: A mitochondrially-targeted gentisic acid derivative exerts antiplatelet action via mitochondrial complex I inhibition"
Article Title: PSG6: A mitochondrially-targeted gentisic acid derivative exerts antiplatelet action via mitochondrial complex I inhibition
Journal: Redox Biology
doi: 10.1016/j.redox.2026.104200
Figure Legend Snippet: PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. (H–I) PFA-200 closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Techniques Used: Expressing, Control, Fluorescence, Microscopy, Shear
Related Articles
In Vivo:Article Title: Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures Article Snippet: .. The Article Title: Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures Article Snippet: .. The Recombinant:Article Title: Poster Abstracts Article Snippet: .. Primary hemostasis and platelet function were evaluated using Shear:Article Title: Quality Assurance in Platelet Function Testing. Article Snippet: Platelets play a key role in hemostasis.. 1,2 Platelet disorders include quantitative, qualitative, and combined disorders and can be congenital or acquired.. The exact frequency of inherited platelet disorders (IPDs) is unknown, but is estimated to be similar to that of von Willebrand disease (VWD). Membrane:Article Title: Quality Assurance in Platelet Function Testing. Article Snippet: Platelets play a key role in hemostasis.. 1,2 Platelet disorders include quantitative, qualitative, and combined disorders and can be congenital or acquired.. The exact frequency of inherited platelet disorders (IPDs) is unknown, but is estimated to be similar to that of von Willebrand disease (VWD). Sampling:Article Title: Dynamic platelet dysfunction during extracorporeal membrane oxygenation: a pilot study. Article Snippet: 2010 to 2017, bleeding events occurred in 37% of patients on veno-venous (VV) ECMO and 62.1% on veno-arterial (VA) ECMO [4, 5].. The shear stress exerted by ECMO systems disrupts physiological hemostasis, leading to reduced platelet count and function, acquired von Willebrand syndrome (AVWS), and activation of both extrinsic and intrinsic coagulation pathways.. This occurs due to the exposure of the patient’s blood to artificial surfaces, contributing to an increased risk of bleeding [3, 6]. |